Sanjay Shukla

This profile gathers the share dealings of Sanjay Shukla in aTYR PHARMA Inc, where the filings describe the role as chief executive. We count 13 filings; the first trade dates from 18 May 2021 and the latest from 3 February 2026.

Purchases make up the whole of the open-market record (9 purchases, €209k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 4 option exercises.

A typical purchase (the median) is worth €28k. 2 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 4 February 2026: an option exercise, in aTYR PHARMA Inc. The clock since the last published purchase (3 June 2024) now reads 867 days. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.